An Observational Chart Review of a Comparison of Generic to Reference Liposome-Encapsulated Doxorubicin Hydrochloride in Subjects with Epithelial Ovarian Carcinoma Who Have Failed Platinum-Based Chemotherapy

This study tested for the effects of generic liposome-encapsulated doxorubicin hydrochloride (generic doxorubicin) compared to reference-pegylated liposomal doxorubicin hydrochloride (reference doxorubicin) as a treatment for patients afflicted with epithelial ovarian carcinoma whose disease has progressed after platinum-based chemotherapy. Chart-reviews of actual patients enrolled in a community-based NIH trial suggest that both generic and reference liposomal doxorubicin hydrochloride (HCl) are equally effective as treatment for ovarian cancer carcinoma.